IOmet Pharma Demonstrates Superior In Vivo PK/PD Properties In Pre-Clinical IDO, TDO And Dual IDO/TDO Cancer Immunotherapy Programs

EDINBURGH, Scotland--(BUSINESS WIRE)--IOmet Pharma, a privately-held company focused on cancer immunotherapy and cancer metabolism, will present data demonstrating superior pharmacokinetic / pharmacodynamic (PK/PD) properties in its pre-clinical IDO, TDO and IDO/TDO Dual Inhibitor programs. The data will be presented at the Immunotherapy of Cancer (ITOC) meeting in Munich, Germany on March 25 & 26.

Help employers find you! Check out all the jobs and post your resume.